Cardiovascular manifestations in Marfan syndrome and related diseases; multiple genes causing similar phenotypes

Cardiovascular abnormalities are the major cause of morbidity and mortality in Marfan syndrome (MFS) and a few clinically related diseases that share, with MFS, the pathogenic contribution of dysregulated transforming growth factor β (TGFβ) signaling. They include Loeys–Dietz syndrome, Shprintzen–Go...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical genetics 2015-01, Vol.87 (1), p.11-20
Hauptverfasser: Cook, J.R., Carta, L., Galatioto, J., Ramirez, F.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 20
container_issue 1
container_start_page 11
container_title Clinical genetics
container_volume 87
creator Cook, J.R.
Carta, L.
Galatioto, J.
Ramirez, F.
description Cardiovascular abnormalities are the major cause of morbidity and mortality in Marfan syndrome (MFS) and a few clinically related diseases that share, with MFS, the pathogenic contribution of dysregulated transforming growth factor β (TGFβ) signaling. They include Loeys–Dietz syndrome, Shprintzen–Goldberg syndrome, aneurysm–osteoarthritis syndrome and syndromic thoracic aortic aneurysms. Unlike the causal association of MFS with mutations in an extracellular matrix protein (ECM), the aforementioned conditions are due to defects in components of the TGFβ pathway. While TGFβ antagonism is being considered as a potential new therapy for these heritable syndromes, several points still need to be clarified in relevant animal models before this strategy could be safely applied to patients. Among others, unresolved issues include whether elevated TGFβ signaling is responsible for all MFS manifestations and is the common trigger of disease in MFS and related conditions. The scope of our review is to highlight the clinical and experimental findings that have forged our understanding of the natural history and molecular pathogenesis of cardiovascular manifestations in this group of syndromic conditions.
doi_str_mv 10.1111/cge.12436
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1647012153</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1647012153</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5236-ce09996a0ef287efab20bbee590a6bd83d6aef7aeb78428e5eabe3b5c84ce7fc3</originalsourceid><addsrcrecordid>eNqNkk1v1DAQhi0EokvhwB9AlrjAIa0dx44tTmjVLqDycVjE0Zo4k8UlcYKdAPvv8bJtD0hI-DKy9cwjzbwm5ClnZzyfc7fDM15WQt0jKy6MKRhj1X2yysUUhitxQh6ldJ2vopbmITkpK63q_L4i0xpi68cfkNzSQ6QDBN9hmmH2Y0jUB_oeYgeBpn1o4zgghdDSiD3M2NLWJ4SE6RUdln72U490hwETdbAkH3Y0-cEftNNXDOO8nzA9Jg866BM-uamn5PPlxXb9prj6uHm7fn1VOFkKVThkxhgFDLtS19hBU7KmQZSGgWpaLVoF2NWATa2rUqNEaFA00unKYd05cUpeHL1THL8veSI7-OSw7yHguCTLVVUzXnIp_gPNO9W8liyjz_9Cr8clhjzIgdKVUVroTL08Ui6OKUXs7BT9AHFvObOHxGxOzP5JLLPPboxLM2B7R95GlIHzI_DT97j_t8muNxe3yuLY4dOMv-46IH6zqs4_wH75sLHby3dMfpKV3Yrf73exFQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1638496838</pqid></control><display><type>article</type><title>Cardiovascular manifestations in Marfan syndrome and related diseases; multiple genes causing similar phenotypes</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Cook, J.R. ; Carta, L. ; Galatioto, J. ; Ramirez, F.</creator><creatorcontrib>Cook, J.R. ; Carta, L. ; Galatioto, J. ; Ramirez, F.</creatorcontrib><description>Cardiovascular abnormalities are the major cause of morbidity and mortality in Marfan syndrome (MFS) and a few clinically related diseases that share, with MFS, the pathogenic contribution of dysregulated transforming growth factor β (TGFβ) signaling. They include Loeys–Dietz syndrome, Shprintzen–Goldberg syndrome, aneurysm–osteoarthritis syndrome and syndromic thoracic aortic aneurysms. Unlike the causal association of MFS with mutations in an extracellular matrix protein (ECM), the aforementioned conditions are due to defects in components of the TGFβ pathway. While TGFβ antagonism is being considered as a potential new therapy for these heritable syndromes, several points still need to be clarified in relevant animal models before this strategy could be safely applied to patients. Among others, unresolved issues include whether elevated TGFβ signaling is responsible for all MFS manifestations and is the common trigger of disease in MFS and related conditions. The scope of our review is to highlight the clinical and experimental findings that have forged our understanding of the natural history and molecular pathogenesis of cardiovascular manifestations in this group of syndromic conditions.</description><identifier>ISSN: 0009-9163</identifier><identifier>EISSN: 1399-0004</identifier><identifier>DOI: 10.1111/cge.12436</identifier><identifier>PMID: 24867163</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>angiotensin receptor blockers (ARBs) ; Animals ; Aortic Aneurysm, Thoracic - genetics ; Aortic Aneurysm, Thoracic - physiopathology ; Arachnodactyly - genetics ; Arachnodactyly - physiopathology ; calcium channel blockers ; cardiomyopathy ; Cardiovascular Abnormalities - genetics ; Cardiovascular Abnormalities - physiopathology ; Cardiovascular disease ; connective tissue ; Craniosynostoses - genetics ; Craniosynostoses - physiopathology ; Fibrillin-1 ; Fibrillins ; Gene therapy ; Ghent nosology ; Humans ; Loeys-Dietz Syndrome - genetics ; Loeys-Dietz Syndrome - physiopathology ; Marfan syndrome ; Marfan syndrome (MFS) ; Marfan Syndrome - genetics ; Marfan Syndrome - physiopathology ; Marfan Syndrome - therapy ; Mice ; Microfilament Proteins - genetics ; Mortality ; mutations in gene for fibrillin-1 (FBN1) ; Signal Transduction - genetics ; TGFβ ; thoracic and abdominal aortic aneurysm ; Transforming Growth Factor beta - antagonists &amp; inhibitors ; Transforming Growth Factor beta - metabolism ; valvulopathy ; β-blockers</subject><ispartof>Clinical genetics, 2015-01, Vol.87 (1), p.11-20</ispartof><rights>2014 John Wiley &amp; Sons A/S. Published by John Wiley &amp; Sons Ltd</rights><rights>2014 John Wiley &amp; Sons A/S. Published by John Wiley &amp; Sons Ltd.</rights><rights>2015 John Wiley &amp; Sons A/S. Published by John Wiley &amp; Sons Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5236-ce09996a0ef287efab20bbee590a6bd83d6aef7aeb78428e5eabe3b5c84ce7fc3</citedby><cites>FETCH-LOGICAL-c5236-ce09996a0ef287efab20bbee590a6bd83d6aef7aeb78428e5eabe3b5c84ce7fc3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fcge.12436$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fcge.12436$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>315,781,785,1418,27929,27930,45579,45580</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24867163$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cook, J.R.</creatorcontrib><creatorcontrib>Carta, L.</creatorcontrib><creatorcontrib>Galatioto, J.</creatorcontrib><creatorcontrib>Ramirez, F.</creatorcontrib><title>Cardiovascular manifestations in Marfan syndrome and related diseases; multiple genes causing similar phenotypes</title><title>Clinical genetics</title><addtitle>Clin Genet</addtitle><description>Cardiovascular abnormalities are the major cause of morbidity and mortality in Marfan syndrome (MFS) and a few clinically related diseases that share, with MFS, the pathogenic contribution of dysregulated transforming growth factor β (TGFβ) signaling. They include Loeys–Dietz syndrome, Shprintzen–Goldberg syndrome, aneurysm–osteoarthritis syndrome and syndromic thoracic aortic aneurysms. Unlike the causal association of MFS with mutations in an extracellular matrix protein (ECM), the aforementioned conditions are due to defects in components of the TGFβ pathway. While TGFβ antagonism is being considered as a potential new therapy for these heritable syndromes, several points still need to be clarified in relevant animal models before this strategy could be safely applied to patients. Among others, unresolved issues include whether elevated TGFβ signaling is responsible for all MFS manifestations and is the common trigger of disease in MFS and related conditions. The scope of our review is to highlight the clinical and experimental findings that have forged our understanding of the natural history and molecular pathogenesis of cardiovascular manifestations in this group of syndromic conditions.</description><subject>angiotensin receptor blockers (ARBs)</subject><subject>Animals</subject><subject>Aortic Aneurysm, Thoracic - genetics</subject><subject>Aortic Aneurysm, Thoracic - physiopathology</subject><subject>Arachnodactyly - genetics</subject><subject>Arachnodactyly - physiopathology</subject><subject>calcium channel blockers</subject><subject>cardiomyopathy</subject><subject>Cardiovascular Abnormalities - genetics</subject><subject>Cardiovascular Abnormalities - physiopathology</subject><subject>Cardiovascular disease</subject><subject>connective tissue</subject><subject>Craniosynostoses - genetics</subject><subject>Craniosynostoses - physiopathology</subject><subject>Fibrillin-1</subject><subject>Fibrillins</subject><subject>Gene therapy</subject><subject>Ghent nosology</subject><subject>Humans</subject><subject>Loeys-Dietz Syndrome - genetics</subject><subject>Loeys-Dietz Syndrome - physiopathology</subject><subject>Marfan syndrome</subject><subject>Marfan syndrome (MFS)</subject><subject>Marfan Syndrome - genetics</subject><subject>Marfan Syndrome - physiopathology</subject><subject>Marfan Syndrome - therapy</subject><subject>Mice</subject><subject>Microfilament Proteins - genetics</subject><subject>Mortality</subject><subject>mutations in gene for fibrillin-1 (FBN1)</subject><subject>Signal Transduction - genetics</subject><subject>TGFβ</subject><subject>thoracic and abdominal aortic aneurysm</subject><subject>Transforming Growth Factor beta - antagonists &amp; inhibitors</subject><subject>Transforming Growth Factor beta - metabolism</subject><subject>valvulopathy</subject><subject>β-blockers</subject><issn>0009-9163</issn><issn>1399-0004</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkk1v1DAQhi0EokvhwB9AlrjAIa0dx44tTmjVLqDycVjE0Zo4k8UlcYKdAPvv8bJtD0hI-DKy9cwjzbwm5ClnZzyfc7fDM15WQt0jKy6MKRhj1X2yysUUhitxQh6ldJ2vopbmITkpK63q_L4i0xpi68cfkNzSQ6QDBN9hmmH2Y0jUB_oeYgeBpn1o4zgghdDSiD3M2NLWJ4SE6RUdln72U490hwETdbAkH3Y0-cEftNNXDOO8nzA9Jg866BM-uamn5PPlxXb9prj6uHm7fn1VOFkKVThkxhgFDLtS19hBU7KmQZSGgWpaLVoF2NWATa2rUqNEaFA00unKYd05cUpeHL1THL8veSI7-OSw7yHguCTLVVUzXnIp_gPNO9W8liyjz_9Cr8clhjzIgdKVUVroTL08Ui6OKUXs7BT9AHFvObOHxGxOzP5JLLPPboxLM2B7R95GlIHzI_DT97j_t8muNxe3yuLY4dOMv-46IH6zqs4_wH75sLHby3dMfpKV3Yrf73exFQ</recordid><startdate>201501</startdate><enddate>201501</enddate><creator>Cook, J.R.</creator><creator>Carta, L.</creator><creator>Galatioto, J.</creator><creator>Ramirez, F.</creator><general>Blackwell Publishing Ltd</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>201501</creationdate><title>Cardiovascular manifestations in Marfan syndrome and related diseases; multiple genes causing similar phenotypes</title><author>Cook, J.R. ; Carta, L. ; Galatioto, J. ; Ramirez, F.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5236-ce09996a0ef287efab20bbee590a6bd83d6aef7aeb78428e5eabe3b5c84ce7fc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>angiotensin receptor blockers (ARBs)</topic><topic>Animals</topic><topic>Aortic Aneurysm, Thoracic - genetics</topic><topic>Aortic Aneurysm, Thoracic - physiopathology</topic><topic>Arachnodactyly - genetics</topic><topic>Arachnodactyly - physiopathology</topic><topic>calcium channel blockers</topic><topic>cardiomyopathy</topic><topic>Cardiovascular Abnormalities - genetics</topic><topic>Cardiovascular Abnormalities - physiopathology</topic><topic>Cardiovascular disease</topic><topic>connective tissue</topic><topic>Craniosynostoses - genetics</topic><topic>Craniosynostoses - physiopathology</topic><topic>Fibrillin-1</topic><topic>Fibrillins</topic><topic>Gene therapy</topic><topic>Ghent nosology</topic><topic>Humans</topic><topic>Loeys-Dietz Syndrome - genetics</topic><topic>Loeys-Dietz Syndrome - physiopathology</topic><topic>Marfan syndrome</topic><topic>Marfan syndrome (MFS)</topic><topic>Marfan Syndrome - genetics</topic><topic>Marfan Syndrome - physiopathology</topic><topic>Marfan Syndrome - therapy</topic><topic>Mice</topic><topic>Microfilament Proteins - genetics</topic><topic>Mortality</topic><topic>mutations in gene for fibrillin-1 (FBN1)</topic><topic>Signal Transduction - genetics</topic><topic>TGFβ</topic><topic>thoracic and abdominal aortic aneurysm</topic><topic>Transforming Growth Factor beta - antagonists &amp; inhibitors</topic><topic>Transforming Growth Factor beta - metabolism</topic><topic>valvulopathy</topic><topic>β-blockers</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cook, J.R.</creatorcontrib><creatorcontrib>Carta, L.</creatorcontrib><creatorcontrib>Galatioto, J.</creatorcontrib><creatorcontrib>Ramirez, F.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical genetics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cook, J.R.</au><au>Carta, L.</au><au>Galatioto, J.</au><au>Ramirez, F.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cardiovascular manifestations in Marfan syndrome and related diseases; multiple genes causing similar phenotypes</atitle><jtitle>Clinical genetics</jtitle><addtitle>Clin Genet</addtitle><date>2015-01</date><risdate>2015</risdate><volume>87</volume><issue>1</issue><spage>11</spage><epage>20</epage><pages>11-20</pages><issn>0009-9163</issn><eissn>1399-0004</eissn><abstract>Cardiovascular abnormalities are the major cause of morbidity and mortality in Marfan syndrome (MFS) and a few clinically related diseases that share, with MFS, the pathogenic contribution of dysregulated transforming growth factor β (TGFβ) signaling. They include Loeys–Dietz syndrome, Shprintzen–Goldberg syndrome, aneurysm–osteoarthritis syndrome and syndromic thoracic aortic aneurysms. Unlike the causal association of MFS with mutations in an extracellular matrix protein (ECM), the aforementioned conditions are due to defects in components of the TGFβ pathway. While TGFβ antagonism is being considered as a potential new therapy for these heritable syndromes, several points still need to be clarified in relevant animal models before this strategy could be safely applied to patients. Among others, unresolved issues include whether elevated TGFβ signaling is responsible for all MFS manifestations and is the common trigger of disease in MFS and related conditions. The scope of our review is to highlight the clinical and experimental findings that have forged our understanding of the natural history and molecular pathogenesis of cardiovascular manifestations in this group of syndromic conditions.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>24867163</pmid><doi>10.1111/cge.12436</doi><tpages>10</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0009-9163
ispartof Clinical genetics, 2015-01, Vol.87 (1), p.11-20
issn 0009-9163
1399-0004
language eng
recordid cdi_proquest_miscellaneous_1647012153
source MEDLINE; Access via Wiley Online Library
subjects angiotensin receptor blockers (ARBs)
Animals
Aortic Aneurysm, Thoracic - genetics
Aortic Aneurysm, Thoracic - physiopathology
Arachnodactyly - genetics
Arachnodactyly - physiopathology
calcium channel blockers
cardiomyopathy
Cardiovascular Abnormalities - genetics
Cardiovascular Abnormalities - physiopathology
Cardiovascular disease
connective tissue
Craniosynostoses - genetics
Craniosynostoses - physiopathology
Fibrillin-1
Fibrillins
Gene therapy
Ghent nosology
Humans
Loeys-Dietz Syndrome - genetics
Loeys-Dietz Syndrome - physiopathology
Marfan syndrome
Marfan syndrome (MFS)
Marfan Syndrome - genetics
Marfan Syndrome - physiopathology
Marfan Syndrome - therapy
Mice
Microfilament Proteins - genetics
Mortality
mutations in gene for fibrillin-1 (FBN1)
Signal Transduction - genetics
TGFβ
thoracic and abdominal aortic aneurysm
Transforming Growth Factor beta - antagonists & inhibitors
Transforming Growth Factor beta - metabolism
valvulopathy
β-blockers
title Cardiovascular manifestations in Marfan syndrome and related diseases; multiple genes causing similar phenotypes
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-11T16%3A45%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cardiovascular%20manifestations%20in%20Marfan%20syndrome%20and%20related%20diseases;%20multiple%20genes%20causing%20similar%20phenotypes&rft.jtitle=Clinical%20genetics&rft.au=Cook,%20J.R.&rft.date=2015-01&rft.volume=87&rft.issue=1&rft.spage=11&rft.epage=20&rft.pages=11-20&rft.issn=0009-9163&rft.eissn=1399-0004&rft_id=info:doi/10.1111/cge.12436&rft_dat=%3Cproquest_cross%3E1647012153%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1638496838&rft_id=info:pmid/24867163&rfr_iscdi=true